Physiological Effects of Fungicides Course for Advisers Koldkaergaard / Aarhus, September 6th 2012 Physiological Effects of Fungicides Physiological Effects of Fungicides: Guidelines for presentation Life can only be understood backwards; but it must be lived forwards Motto for advise in plant protection: As little as possible but as much as neccessary
Therefore, it is necessary to see your doctor about any defects priligy australia but also by those who experience temporary dip in sexual activeness.
MaquetaciónMetabolic Syndrome Metabolic Syndrome Anejo Health Communications // Pocket Guide to Metabolic Syndrome Metabolic Syndrome Peter Steinberg Anejo Health Communications Anejo Health Communications Address: Lavalle 715 5th floor. (1047) Bs. As. - ArgentinaPhone: (011) 4322-1110 / 1199 / 0109E-mail: email@example.com First edition June 2012All rights reservedPrinted in June 2012 Although the information about medication given in this book hasbeen carefully checked, the author and publisher accept no liability forthe accuracy of this information. In every individual case the user must check such information by consultingthe relevant literature.
This work is subject to copyright. All rights are reserved, whether thewhole or part of the material is concerned, specifically the rights oftranslation, reprinting, reuse of illustrations, recitation, broadcasting,reproduction on microfilm or in any other way, and storage in data banks.
ISBN 978-950-9647-85-5 // Pocket Guide to Metabolic Syndrome Table of Contents History of Metabolic Syndrome
. Type 1 Diabetes, Type 2 Diabetes, and Insulin Resistance. A Precursor to Cardiovascular Disease and Diabetes Developing - and reconciling a formal definition
Population differences in prevalence
Diagnosis Metabolic Syndrome
. Medical History . Waist Circumference . Measuring Waist Circumference . Measuring Blood Pressure Laboratory Test
. Assessing Insulin Resistance
. Assessing Dyslipidemia Two possible accompanyng diagnosis
. Cushing's Syndrome Causes of Metabolic Syndrome
. Intra-Abdominal Obesity . Insulin Resistence . Urinary Symptoms in Men The health consequences
. Coronary heart disease . Type 2 diabetes Treatment of Metabolic Syndrome
. Goals of Treatment . Healthy Lifestyle Changes . Psychological Counseling Prevention of Metabolic Syndrome
. Physical Activity . Routine Health Maintenance // Pocket Guide to Metabolic Syndrome Introduction Metabolic syndrome is a term used to describe a particular clusterof health problems that were first identified in 1988 by Gerald Rea-ven, an endocrinologist at Stanford University.1 He originally calledit syndrome X, and at various times the syndrome has also been re-ferred to as dysmetabolic syndrome, insulin resistance syndrome, andobesity dyslipidemia syndrome. The term metabolic syndrome is nowwidely accepted, whereas syndrome X fell into disfavor due to con-fusion with a similarly named cardiac syndrome. In essence, metabolic syndrome is characterized by abdominal obe-sity and insulin resistance (reduced responsiveness of the body tis-sues to insulin). Metabolic syndrome is often accompanied byhypertension and two lipid disorders: high blood levels of triglyce-rides and low blood levels of high-density lipoprotein (HDL) cho-lesterol. Compared to someone without the syndrome, a person withmetabolic syndrome has a fivefold greater risk of developing type 2diabetes, and is three times as likely to have – and twice as likely todie from – a heart attack or stroke.2 A major public health problem, metabolic syndrome affects one-quarter of the world's adults.2 A 2009 study found that individualswith metabolic syndrome incur almost 1.6 times the medical costsof those without the syndrome ($5,732 vs. $3,581 annually). Addi- tionally, annual medical costs were nearly double among individualswith diabetes who had risk factors for metabolic syndrome, compa-red to nondiabetics who had such risk factors ($8,067 vs. $4,638).3 // Pocket Guide to Metabolic Syndrome History of MetabolicSyndrome Type 1 Diabetes, Type 2 Diabetes, and Insulin Resistance In the early 1920s, the Canadian surgeon Frederick Banting and hisassistant Charles Best, a medical student, extracted a compound theynamed insulin from the islets of Langerhans in the pancreas. Wheninjected into diabetic dogs, the compound decreased the levels of sugarin the dogs' blood and urine.4 The discovery, coupled with the purifi-cation of insulin, helped transform childhood diabetes from a fataldisease to a chronic illness.
By the 1930s, it had become common to classify people with diabetesaccording to how they reacted to an injection of insulin. Those whowere "insulin-sensitive" or "insulin-dependent" were found to easilyprocess an oral dose of glucose when also given a subcutaneous insulininjection. On the other hand, "insulin-insensitive" or "non-insulin-dependent" diabetics did not experience a significant reduction inblood glucose after receiving the same amount of insulin.
Today, most people use the term type 1 diabetes to refer to what used
to be known as "insulin-sensitive" or "insulin-dependent" diabetes.
Type 1 diabetes results from an autoimmune reaction whereby the
body's defense system attacks insulin-producing cel s, although the rea-
son for this is not entirely understood. Individuals with type 1 diabetesproduce little or no insulin. Although the disease can strike at any age,it occurs more often in children and young adults, and is sometimescalled juvenile-onset diabetes. People with type 1 diabetes require dailyinjections of insulin in order to control their blood glucose levels.5 Type 2 diabetes has largely replaced the terms "insulin-insensitive"
and "non-insulin-dependent" diabetes. Type 2 accounts for at least
90% of all cases of diabetes, and is sometimes referred to as adult-
onset diabetes because it usually arises in adults over the age of 40, al-
though it can occur at any age, especially in populations with high
diabetes prevalence. This type of diabetes is characterized by insulin
resistance, a phenomenon by which an individual's body tissues have
a diminished response to insulin, causing the body to produce larger
quantities of insulin to maintain normal blood glucose levels.5,6
By the late 1980s insulin resistance had become an important field of
research, as physicians began to understand it not only as a precondi-
tion of type 2 diabetes, but as also associated with conditions such as
obesity, pre-diabetes (a condition marked by elevated blood glucose
levels after fasting or after a 2-hour glucose tolerance test), heart dis-
ease, and polycystic ovarian syndrome (PCOS), an endocrine disor-
der that affects 3-10% of premenopausal women as a result of the
formation of cysts in the ovaries, leading to irregular menstrual peri-
ods, infertility, hirsutism (excess body hair), or other indications of
high blood levels of androgens (male sex hormones).6
With the emergence of insulin resistance as a public health and clinicalproblem, researchers increasingly recognized that it frequently pre-sented as part of a particular cluster of metabolic disorders that alsoincluded intra-abdominal obesity, high blood levels of triglycerides,low blood levels of HDL cholesterol, and high blood pressure. Thiscluster appeared to meet the criteria of a syndrome: "a clustering offactors that occur together more often than by chance alone and forwhich the cause is often uncertain."7 // Pocket Guide to Metabolic Syndrome A Precursor to Cardiovascular Disease and Diabetes Although there is general agreement within the medical community thatmetabolic syndrome deserves greater attention, there has been widespreaddisagreement with regard to the terminology and diagnostic criteria relatedto the syndrome. Nevertheless, there appears to be a consensus amongphysicians that the term metabolic syndrome is an acceptable way to de-scribe the presence of multiple risk factors for cardiovascular disease(CVD) and diabetes. On the other hand, several clinical definitions ofmetabolic syndrome have been proposed (as discussed below), causingsome confusion among clinicians in terms of how to identify patients whohave the syndrome.7 Some of the confusion may reflect the complexity and interrelatedness
of the factors that contribute to metabolic syndrome. The syndrome is
not an indicator of absolute risk because it does not include many of the
factors that determine absolute risk of disease, such as age, sex, cigarette
smoking, and low-density lipoprotein (LDL) cholesterol levels. Neverthe-
less, it is wel known that metabolic syndrome increases the risk of CVD
and type 2 diabetes.7,8 Moreover, the most widely recognized metabolic
risk factors – dyslipidemia, high blood pressure, and elevated plasma glu-
cose – often manifest as a prothrombotic and proinflammatory state. Most
persons with metabolic syndrome have abdominal obesity and insulin re-
sistance, both of which appear to contribute to the development of meta-
bolic risk factors, although the mechanisms for these contributions are
not completely understood.7
The most common clinical definition of metabolic syndrome uses a smalset of direct measurements: waist circumference, elevated triglycerides, re-duced HDL cholesterol, elevated blood pressure, and elevated fasting glu-cose.7 These measurements can facilitate an objective diagnosis of thesyndrome, while also providing actionable targets for basic research, drugdevelopment, and therapeutic advances. As currently defined, metabolic syndrome is a useful but imperfect pre-dictor of a person's chance of developing serious health problems. As thesyndrome continues to draw researchers' attention, its definition wil likelyevolve.
// Pocket Guide to Metabolic Syndrome 1. Reaven G, Strom T, Fox B. Syndrome X: Overcoming the SilentKiller That Can Give You a Heart Attack. New York: Simon & Schus-ter; 2000.
2. International Diabetes Federation. IDF worldwide definition of themetabolic syndrome. Brussels, Belgium: International Diabetes Fed-eration; 2011. Retrieved August 2012 from http://www.idf.org/meta-bolic-syndrome. 3. Boudreau DM, Malone DC, Raebel MA, et al. Health care utilizationand costs by metabolic syndrome risk factors. Metabolic Syndromeand Related Disorders. 2009;7(4):305-14.
4. Banting FG, Best CH, Coll JB, Campbell WR, Fletcher AA. Pancre-atic extracts in the treatment of diabetes mellitus. Canadian MedicalAssociation Journal. 1922 Mar;12(3):141-6.
5. International Diabetes Federation. Types of diabetes. Brussels, Bel-gium: International Diabetes Federation; 2011. Retrieved August 2012from http://www.idf.org/types-diabetes.
6. Insulin resistance. Gale Encyclopedia of Medicine. The Gale Group,Inc.; 2008. Retrieved August 2012 from http://medical-dictionary.the-freedictionary.com/insulin+resistance.
7. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing themetabolic syndrome: a joint interim statement of the International Di-abetes Federation Task Force on Epidemiology and Prevention; Na-tional Heart, Lung, and Blood Institute; American Heart Association;World Heart Federation; International Atherosclerosis Society; and In-ternational Association for the Study of Obesity. Circulation.
8. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cho-lesterol Education Program: Adult Treatment Panel III, InternationalDiabetes Federation, and World Health Organization Definitions ofthe metabolic syndrome as predictors of incident cardiovascular dis-ease and diabetes. Diabetes Care. 2007;30(1): 8–13.
9. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome:time for a critical appraisal. Diabetes Care. 2005;28:2289-2304.
10. Grundy S. Does the metabolic syndrome exist? Diabetes Care.
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classificationof diabetes mellitus and its complications, part 1: diagnosis and clas-sification of diabetes mellitus. Provisional report of a WHO consul-tation. Diabetic Medicine. 1998;15(7):539-53. 12. National Cholesterol Education Program (NCEP) Expert Panelon Detection, Evaluation, and Treatment of High Blood Cholesterolin Adults (Adult Treatment Panel III). Third Report of the NationalCholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults (AdultTreatment Panel III) final report. Circulation. 2002;106:3143-421.
13. International Diabetes Federation. The IDF Consensus WorldwideDefinition of the Metabolic Syndrome. Brussels, Belgium: Interna-tional Diabetes Federation; 2006.
14. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and manage-ment of the metabolic syndrome: an American Heart Association/Na- tional Heart, Lung, and Blood Institute scientific statement. Circula-tion. 2005;112: 2735-52.
15. National Institutes of Health. Clinical Guidelines on the Identifi-cation, Evaluation, and Treatment of Overweight and Obesity inAdults: the Evidence Report. Bethesda, MD: National Institutes ofHealth; 1998. NIH Publication No. 98-4083.
16. Ervin RB. Prevalence of metabolic syndrome among adults 20 yearsof age and over, by sex, age, race and ethnicity, and body mass index:United States, 2003-2006. National Health Statistics Reports; No. 13.
Hyattsvil e, Md: National Center for Health Statistics; 2009. RetrievedAugust 2012 from http://www.cdc.gov/nchs/data/nhsr/nhsr013.pdf.
17. Misra R, Patel T, Kotha P, et al. Prevalence of diabetes, metabolicsyndrome, and cardiovascular risk factors in US Asian Indians: resultsfrom a national study. Journal of Diabetes and its Complications.
18. Cook S, Auinger P, Li C, Ford ES. Metabolic syndrome rates inUnited States adolescents, from the National Health and Nutrition Ex-amination Survey, 1999-2002. Journal of Pediatrics. 2008;152: 165-70.
19. Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-spe-cific prevalence of the metabolic syndrome defined by the Interna-tional Diabetes Federation and the National Cholesterol EducationProgram: the Norwegian HUNT 2 study. BMC Public Health.
20. Gündogan K, Bayram F, Capak M, et al. Prevalence of metabolicsyndrome in the Mediterranean region of Turkey: evaluation of hy-pertension, diabetes mel itus, obesity, and dyslipidemia. Metabolic Syn-drome and Related Disorders. 2009;7(5):427-34.
21. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R.
First nationwide study of the prevalence of the metabolic syndromeand optimal cutoff points of waist circumference in the Middle East.
Diabetes Care. 2009;32:1092-7.
22. Yang W, Reynolds K, Gu D, Chen J, He J. A comparison of twoproposed definitions for metabolic syndrome in the Chinese adultpopulation. American Journal of Medical Science. 2007;334(3):184-9.
23. Yoon YS, Lee ES, Park C, Lee S, Oh SW. The new definition ofmetabolic syndrome by the International Diabetes Federation is lesslikely to identify metabolically abnormal but non-obese individualsthan the definition by the revised National Cholesterol Education Pro-gram: the Korea NHANES Study. International Journal of Obesity.
24. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolicsyndrome in patients with gout: The Third National Health and Nu-trition Examination Survey. Arthritis Care & Research. 2007;57(1):109-15.
25. Parish JM, Adam T, Facchiano L. Relationship of metabolic syn-drome and obstructive sleep apnea. Journal of Clinical Sleep Medicine.
26. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, StuckeyBG. Cardiometabolic risk in polycystic ovary syndrome: a comparisonof different approaches to defining the metabolic syndrome. HumanReproduction. 2008;23(10): 2352-8.
27. Bultink IE, Turkstra F, Diamant M, Dijkmans BA, Voskuyl AE.
Prevalence of and risk factors for the metabolic syndrome in womenwith systemic lupus erythematosus. Clinical and ExperimentalRheumatology. 2008;26(1): 32-8.
28. Chung CP, Avalos I, Oeser A, et al. High prevalence of the meta-bolic syndrome in patients with systemic lupus erythematosus: Asso-ciation with disease characteristics and cardiovascular risk factors.
Annals of Rheumatic Diseases. 2007;66(2): 208–14.
29. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome andchronic kidney disease in U.S. Adults. Annals of Internal Medicine.
// Pocket Guide to Metabolic Syndrome 30. Moore JB. Non-alcoholic fatty liver disease: the hepatic conse-quence of obesity and the metabolic syndrome. Proceedings of theNutrition Society. 2010;69(2):211-20.
31. Roos A, Bakker SJL, Links TP, Gans ROB, Wolffenbuttel BHR.
Thyroid function is associated with components of the metabolic syn-drome in euthyroid subjects. Journal of Clinical Endocrinology & Me-tabolism. 2007;92(2):491-6.
32. Roberts RO, Geda YE, Knopman DS, et al. Metabolic syndrome,inflammation, and non-amnestic mild cognitive impairment in olderpersons: a population-based study. Alzheimer Disease and AssociatedDisorders. 2010;24(1):11-8.
33. Vanhanen M, Koivisto K, Moilanen L, et al. Association of meta-bolic syndrome with Alzheimer disease: a population-based study.
34. Abdollah F, Briganti A, Suardi N, et al. Metabolic syndrome andbenign prostatic hyperplasia: evidence of a potential relationship, hy-pothesized etiology, and prevention. Korean Journal of Urology.
35. Loevenger BL, Muller D, Alonso C, Coe CL. Metabolic syndromein women with chronic pain. Metabolism Clinical and Experimental.
36. Sabanayagam C, Wang JJ, Mitchell P, et al. Metabolic syndromecomponents and age-related cataract: the Singapore Malay Eye Study.
Investigative Ophthalmology & Visual Science. 2011;52(5):2397-404.
37. Soto Gonzalez A, Bellido D, Buño MM, et al. Predictors of themetabolic syndrome and correlation with computed axial tomography.
38. Rasouli N, Molavi B, Elbein SC, Kern PA. Ectopic fat accumulationand metabolic syndrome. Diabetes, Obesity and Metabolism. 2007;9(1): 1–10.
39. Phil ips LK, Prins JB. The link between abdominal obesity and themetabolic syndrome. Current Hypertension Reports. 2008;10(2):156-64.
40. World Health Organization. BMI classification. Global Databaseon Body Mass Index. Geneva, Switzerland: World Health Organiza-tion; 41. World Health Organization. Obesity and Overweight. Fact sheetNo. 311. Geneva, Switzerland: World Health Organization; 2012. Re-trieved August 2012 from http://www.who.int/mediacentre/fact-sheets/fs311/en/. 42. National Institutes of Health. The Practical Guide: Identification,Evaluation, and Treatment of Overweight and Obesity in Adults.
Bethesda, MD: National Institutes of Health; 2000. NIH PublicationNo. 00-4084.
43. Zhu S, Wang Z, Shen W, Heymsfield SB, Heshka S. Percentagebody fat ranges associated with metabolic syndrome risk: results basedon the Third National Health and Nutrition Examination Survey(1988-1994). American Journal of Clinical Nutrition. 2003;78:228-35.
44. Park Y-W, Zhu S, Palaniappan L, Heshka S, Carnethon MR,Heymsfield SB. The metabolic syndrome: prevalence and associatedrisk factor findings in the US population from the Third NationalHealth and Nutrition Examination Survey, 1988-1994. Archives of In-ternal Medicine. 2003;163:427-36.
45. Android obesity. Mosby's Medical Dictionary, 8th edition. Elsevier;2009. Retrieved August 2012 from http://medical-dictionary.thefree-dictionary.com/android+obesity. 46. Gynecoid obesity. Mosby's Medical Dictionary, 8th edition. Else-vier; 2009. Retrieved August 2012 from http://medical-dictionary.the-freedictionary.com/gynecoid+obesity.
47. Visceral obesity. Android obesity. Mosby's Medical Dictionary, 8th // Pocket Guide to Metabolic Syndrome edition. Elsevier; 2009. Retrieved August 2012 from http://medical-dictionary.thefreedictionary.com/visceral+obesity.
48. Bosello O, Zamboni M. Visceral obesity and metabolic syndrome.
Obesity Reviews. 2000;1(1):47-56.
49. Willis LH, Slentz CA, Houmard JA, et al. Minimal versus umbilicalwaist circumference measures as indicators of cardiovascular diseaserisk. Obesity. 2007;15(3): 753–59.
50. Beckman JA, Libby P, Creager MA. Diabetes mellitus, the meta-bolic syndrome, and atherosclerotic vascular disease. In Libby P,Bonow RO, Mann DL, Zipes DP (Eds.), Braunwald's Heart Disease:A Textbook of Cardiovascular Medicine, 8th ed. Philadelphia, PA:Saunders; 2008, chapter 43.
51. National Heart Lung and Blood Institute. What Is High BloodPressure? Bethesda, MD: National Institutes of Health; 2012. Re-trieved August 2012 from http://www.nhlbi.nih.gov/health/health-topics/topics/hbp/.
52. Grossman A, Grossman C, Barenboim E, Azaria B, Goldstein L,Grossman E. Pre-hypertension as a predictor of hypertension in mil-itary aviators: a longitudinal study of 367 men. Aviation Space and En-vironmental Medicine. 2006;77(11):1162-5.
53. National Heart Lung and Blood Institute. How is Metabolic Syn-drome Diagnosed? Bethesda, MD: National Institutes of Health; 2012.
Retrieved August 2012 from http://www.nhlbi.nih.gov/health/health-topics/topics/ms/diagnosis.html 54. Harvard Health Publications. Hypertension: control ing the "silentkiller." Harvard Medical School; 2012. Retrieved August 2012 fromhttp://www.health.harvard.edu/special_health_reports/Hypertension.
55. Frese EM, Fick A, Sadowsky HS. Blood pressure measurementguidelines for physical therapists. Cardiopulmonary Physical TherapyJournal. 2011;22(2):5-12.
56. Diabetes. Dorland's Medical Dictionary for Health Consumers.
Saunders; 2007. Retrieved August 2012 from http://medical-dictio-nary.thefreedictionary.com/diabetes.
57. Hyperglycemia. Gale Encyclopedia of Medicine. The Gale Group,Inc.; 2008. Retrieved August 2012 from http://medical-dictionary.the-freedictionary.com/hyperglycemia.
58. American Diabetes Association Standards of medical care in dia-betes—2011. Diabetes Care. 2011; 34(Suppl 1): S11-S61. 59. Dyslipidemia. The Merck Manual Home Health Handbook. White-house Station, NJ: Merck Sharp & Dohme Corp.; 2008. Retrieved August2012 from http://www.merckmanuals.com/home/hormonal_and_meta-bolic_disorders/cholesterol_disorders/dyslipidemia.html#v769868.
60. Cushing's syndrome. The Merck Manual Home Health Handbook. White-house Station, NJ: Merck Sharp & Dohme Corp.; 2007. Retrieved August 2012from http://www.merckmanuals.com/home/hormonal_and_metabolic_dis-orders/adrenal_gland_disorders/cushings_syndrome.html#v772527.
61. Hypothyroidism. The Merck Manual Home Health Handbook. White-house Station, NJ: Merck Sharp & Dohme Corp.; 2012. Retrieved August2012 from http://www.merckmanuals.com/home/hormonal_and_meta-bolic_disorders/thyroid_gland_disorders/hypothyroidism.html?qt=hy-pothyroidism&alt=sh.
62. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat isa major determinant of the National Cholesterol Education ProgramAdult Treatment Panel III Criteria for the metabolic syndrome. Dia-betes. 2004;53(8):2087-94.
63. Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyorala K,DECODE Insulin Study Group. Plasma insulin and cardiovascularmortality in non-diabetic European men and women: a meta-analysisof data from eleven prospective studies. Diabetologia.
2004;47(7):1245-56. // Pocket Guide to Metabolic Syndrome 64. National Heart Lung and Blood Institute. What Causes Overweightand Obesity? Bethesda, MD: National Institutes of Health; 2012. Re-trieved August 2012 from http://www.nhlbi.nih.gov/health/health-topics/topics/obe/causes.html.
65. Malik VS, Popkin BM, Bray GA, Despres JP, Willet WC, Hu, FB.
Sugar-sweetened beverages and risk of metabolic syndrome and type2 diabetes: a meta-analysis. Diabetes Care. 2010;33(11): 2477-83.
66. Yau PL, Castro MG, Tagnani A, Tsui WH, Convit A. Obesity andmetabolic syndrome and functional and structural brain impairmentsin adolescence. Pediatrics. 2012;130(4):1-9.
67. Diabetes Research Working Group. Conquering Diabetes: High-lights of Program Efforts, Research Advances and Opportunities.
Bethesda, MD: National Institute of Diabetes and Digestive and Kid-ney Diseases; 2002. Retrieved September 2012 fromhttp://www2.niddk.nih.gov/NR/rdonlyres/AA112E12-CA42-422C-B371-A31503F58235/0/DWG_Sept_2002_Signaling.pdf.
68. Biggerstaff KD, Wooten JS. Understanding lipoproteins as trans-porters of cholesterol and other lipids. Advanced Physiology Educa-tion. 2004);28:105-6.
69. High blood pressure. The Merck Manual Home Health Handbook. White-house Station, NJ: Merck Sharp & Dohme Corp.; 2007. Retrieved September2012 from http://www.merckmanuals.com/home/heart_and_blood_ves-sel_disorders/high_blood_pressure/high_blood_pressure.html#v717864.
70. Victor RG, Kaplan NM. Systemic hypertension: mechanisms anddiagnosis. In Libby P, Bonow RO, Mann DL, Zipes DP (Eds.), Braun-wald's Heart Disease: A Textbook of Cardiovascular Medicine, 8th ed.
Philadelphia, PA: Saunders; 2008, chapter 40.
71. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: a link be-tween hypertension obesity and glucose intolerance. Journal of ClinicalInvestigation. 1985;75:809-17.
72. Gunderson E, Jacobs DR Jr., Chiang V, et al. Childbearing is asso-ciated with higher incidence of the metabolic syndrome amongwomen of reproductive age control ing for measurements before preg-nancy: the CARDIA study. American Journal of Obstetrics and Gy-necology. 2009;201(2): 177.e1-9.
73. Kupelian V, McVary KT, Kaplan SA, et al. Association of lowerurinary tract symptoms and the metabolic syndrome: results from theBoston Area Community Health Survey. Journal of Urology.
74. Steinmetz A, Fenselau S, Schrezenmeir J. Treatment of dyslipopro-teinemia in the metabolic syndrome. Experimental and Clinical En-docrinology & Diabetes. 2001;109(4):S548-59.
75. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treat-ment and lipid levels with major coronary events. VA-HIT: a random-ized controlled trial. JAMA 2001;285:1585-91.
76. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heartfailure. New England Journal of Medicine. 2002;347:305-13.
77. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndromeand risk of development of atrial fibrillation: the Nigata PreventiveMedicine Study. Circulation. 2008;117:1255-60.
78. Metabolic Syndrome Society. Adverse health effects of metabolicsyndrome. 2011. Retrieved September 2012 from http://www.meta-bolic-syndrome-handbook.com/content/adverse-health-effects-metabolic-syndrome. 79. Centers for Disease Control and Prevention. National DiabetesFact Sheet: national estimates and general information on diabetes andprediabetes in the United States, 2011. Atlanta, GA: U.S. Departmentof Health and Human Services, Centers for Disease Control andPrevention, 2011. Retrieved September 2012 from http://dia-betes.niddk.nih.gov/dm/pubs/statistics/index.htm. // Pocket Guide to Metabolic Syndrome 80. National Heart Lung and Blood Institute. How is Metabolic SyndromeTreated? Bethesda, MD: National Institutes of Health; 2011. RetrievedSeptember 2012 from http://www.nhlbi.nih.gov/health/health-topics/topics/ms/treatment.html.
81. National Heart Lung and Blood Institute. What Is the DASH Eat-ing Plan? Bethesda, MD: National Institutes of Health; 2012. RetrievedSeptember 2012 from http://www.nhlbi.nih.gov/health/health-top-ics/topics/dash/.
82. Kastorini C-M, Milionis HJ, Esposito K, Giugliano D, GoudevenosJA, Panagiotakos DB. The effect of Mediterranean diet on metabolicsyndrome and its components. Journal of the American College ofCardiology 2011;57: 1299-313.
83. United States Department of Health and Human Services (U.S.
DHHS). Physical Activity Guidelines for Americans—At-a-Glance: AFact Sheet for Professionals, 2008. Retrieved September 2012 fromhttp://www.health.gov/PAGuidelines/factsheetprof.aspx.
84. Juturu V, Gormley JJ. Nutritional supplements modulating meta-bolic syndrome risk factors and the prevention of cardiovascular dis-ease. Current Nutrition & Food Science 2005; 205(1): 1–11.
85. Oh SW, Yoon YS, Lee ES, et al. Association between cigarettesmoking and metabolic syndrome: The Korea National Health andNutrition Examination Survey. Diabetes Care 2005;28(8):2064-6.
86. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Wil ett WC. Prospec-tive study of cigarette smoking, alcohol use, and the risk of diabetesin men. BMJ 1995;310:555-9.
87. Bowman TS, Gaziano JM, Buring JE, Sesso HD. A prospec-tive study of cigarette smoking and risk of incident hyperten-sion in women. Journal of the American College of Cardiology.
88. Johnson RK, Appel LJ, Brands M, et al. Dietary sugars intake and cardiovascular health: a scientific statement from the American HeartAssociation. Circulation. 2009;120(11):1011-20.
89. Chobanian AV, Bakris GL, Black HR, et al. The seventh report ofthe Joint National Committee on Prevention, Detection, Evaluation,and Treatment of High Blood Pressure: the JNC 7 report. JAMA.
90. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor block-ade versus converting-enzyme inhibition in type 2 diabetes andnephropathy. New England Journal of Medicine. 2004;351:1952-61.
91. Scheen AJ. Prevention of type 2 diabetes through inhibition of therenin-angiotensin system. Drugs. 2004;64:2537-65.
92. United States Food and Drug Administration (U.S. FDA). FDAdrug safety communication: Updated risk evaluation and mitigationstrategy (REMS) to restrict access to rosiglitazone-containing medicinesincluding Avandia, Avandamet, and Avandaryl, 2011. Retrieved October2012 from http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm.
93. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of my-ocardial infarction and death from cardiovascular causes. New EnglandJournal of Medicine. 2007;356(24): 2457-71.
94. Crosta P. What are statins? How statins work and the side effectsof statins. Medical News Today, April 16, 2009. Bexhill-on-Sea, UK:MediLexicon International Ltd. Retrieved October 2012 fromhttp://www.medicalnewstoday.com/articles/8274.php. 95. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR,Kjekshus J. Influence of low high-density lipoprotein cholesterol andelevated triglyceride on coronary heart disease events and response tosimvastatin therapy in 4S. Circulation. 2001;104:3046-51.
96. Ogbru O. Fibrates (fibric acid). MedicineNet.com; 2012. RetrievedOctober 2012 from http://www.medicinenet.com/fibrates/article.htm. // Pocket Guide to Metabolic Syndrome 97. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin,and cardiovascular disease. Subgroup analysis from the Departmentof Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Archives of Internal Medicine. 2002;162:2597-604.
98. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, andtolerability of once-daily niacin for the treatment of dyslipidemia as-sociated with type 2 diabetes. Archives of Internal Medicine.
99. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits ofniacin by glycemic status in patients with healed myocardial infarction(from the Coronary Drug Project). American Journal of Cardiology.
100. Campbell IW, Haslam DW. Obesity: Your Questions Answered,1st ed. London: Churchill Livingstone, 2005. Chapter 7, Management:Pharmacotherapy: 121-40.
101. United States Food and Drug Administration (U.S. FDA). FDAdrug safety communication: completed safety review of Xenical/Alli(orlistat) and severe liver injury, 2010. Retrieved October 2012 fromhttp://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyIn-formationforPatientsandProviders/ucm213038.htm. 102. Public Citizen. Petition to ban orlistat (Xenical, Alli), 2011. Re-trieved October 2012 from http://www.citizen.org/hrg1942. 103. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 dia-betes after bariatric surgery: Systematic review and meta-analysis.
American Journal of Medicine 2009;122(3): 248-56.
104. National Heart Lung and Blood Institute. How Can Metabolic Syn-drome Be Prevented? Bethesda, MD: National Institutes of Health; 2011.
Retrieved October 2012 from http://www.nhlbi.nih.gov/health/health-topics/topics/ms/prevention.html.
105. American Heart Association. Prevention and treatment of meta- bolic syndrome, 2011. Retrieved October 2012 fromhttp://www.heart.org/HEARTORG/Conditions/More/Metabolic-S y n d r o m e / P r e v e n t i o n - a n d - Tr e a t m e n t - o f - M e t a b o l i c -Syndrome_UCM_301927_Article.jsp. Anejo Health Communications
GUIDELINE WATCH (OCTOBER 2014): PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH ALZHEIMER'S DISEASE AND OTHER DEMENTIAS Peter V. Rabins, M.D., M.P.H.Barry W. Rovner, M.D.Teresa Rummans, M.D.Lon S. Schneider, M.D.Pierre N. Tariot, M.D. During development and approval of this guideline watch, from July 2012 to September 2014, Dr. Rabins reports providing legaltestimony for Janssen Pharmaceutica, Dr. Rovner reports serving as a consultant to GE Healthcare, and Dr. Rummans reports thatshe has nothing to disclose. From 3 years before development was initiated in July 2012 through September 2014, Dr. Schneider andthe University of Southern California received research or other grants from Abbott Laboratories, AstraZeneca, Baxter, Forest Phar-maceuticals, Inc., Forum, Genentech, Johnson & Johnson, Eli Lilly and Company, Lundbeck, Merck, Myriad, Novartis, Pfizer,Roche, and TauRx, Ltd. and from NIH (USC ADRC, ADCS, ADNI, Banner Alzheimer's Initiative, CitAD, phytoSERMs, Alzheim-er's disease trial simulations, allopregnanolone, P50 AG05142, R01 AG033288, R01 AG037561, UF1 AG046148), and the state ofCalifornia (California Alzheimer's Disease Program, California Institute for Regenerative Medicine). During that same time period,Dr. Schneider served as a consultant or on advisory panels for Abbott Laboratories, Abbvie, AC Immune, Accera, Allon, AstraZeneca,Avraham Pharmaceuticals, Ltd., Biogen Idec, Cerespir, Forest Pharmaceuticals, Inc., Forum, GSK, Johnson & Johnson, Eli Lilly andCompany, Lundbeck, Merck, Novartis, Orion, Roche, Servier, Stemedica, Ltd., Takeda, Targacept, TauRx, Toyama/FujiFilm, andZinfandel. In addition, Dr. Schneider serves on the editorial boards of Alzheimer's and Dementia: Translational Research and ClinicalIntervention (editor-in-chief), The Lancet Neurology (editorial board), Cochrane Collaboration (editor base), BMC Psychiatry (section ed-itor), Alzheimer's & Dementia (senior associate editor), Current Alzheimer Research (associate editor), Clinical Neuropharmacology (edi-torial board) and on the guidelines committee for the World Federation of Societies of Biological Psychiatry; served as an expert wit-ness or consultant on federal and state cases for plaintiffs against Lilly, Johnson & Johnson, and Pfizer and for defendants AstraZenecaand Pfizer; and has consulted with the state of California Department of Justice. During development and approval of this guidelinewatch, Dr. Tariot reports receiving consulting fees from Abbott Laboratories, AbbVie, AC Immune, Adamas, Avanir, Avid, Boehringer-Ingelheim, Bristol Myers Squibb, California Pacific Medical Center, Chase Pharmaceuticals, Chiesi, CME, Inc., Cognoptix, Elan,Eli Lilly, GlaxoSmithKline, Janssen, Medavante, Medivation, Merck and Company, Merz, Otsuka, Roche, and Sanofi-Aventis. Dr.Tariot reports receiving research support from AstraZeneca, Avanir, Avid, Baxter Healthcare Corp., Bristol Myers Squibb, Cognop-tix, Eli Lilly, Functional Neuromodulation (f(nm)), GE, Genentech, GlaxoSmithKline, Janssen, Medivation, Merck and Company,Pfizer, Roche, Targacept, and Toyama as well as the National Institute on Aging and the Arizona Department of Health Services. Dr.Tariot also reports stock options in Adamas and that he is listed as a contributor to a patent owned by the University of Rochester,"Biomarkers of Alzheimer's Disease."